These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16076835)

  • 1. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count.
    Cole SR; Hernán MA; Margolick JB; Cohen MH; Robins JM
    Am J Epidemiol; 2005 Sep; 162(5):471-8. PubMed ID: 16076835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.
    Cole SR; Hernán MA; Robins JM; Anastos K; Chmiel J; Detels R; Ervin C; Feldman J; Greenblatt R; Kingsley L; Lai S; Young M; Cohen M; Muñoz A
    Am J Epidemiol; 2003 Oct; 158(7):687-94. PubMed ID: 14507605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model.
    Cole SR; Hernán MA; Anastos K; Jamieson BD; Robins JM
    Am J Epidemiol; 2007 Jul; 166(2):219-27. PubMed ID: 17478436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Marginal structural models application to estimate the effects of antiretroviral therapy in 5 cohorts of HIV seroconverters].
    Pérez-Hoyos S; Ferreros I; Hernán MA;
    Gac Sanit; 2007; 21(1):76-83. PubMed ID: 17306191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.
    Sterling TR; Chaisson RE; Keruly J; Moore RD
    J Infect Dis; 2003 Dec; 188(11):1659-65. PubMed ID: 14639536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death.
    Cole SR; Jacobson LP; Tien PC; Kingsley L; Chmiel JS; Anastos K
    Am J Epidemiol; 2010 Jan; 171(1):113-22. PubMed ID: 19934191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3.
    Hulgan T; Raffanti S; Kheshti A; Blackwell RB; Rebeiro PF; Barkanic G; Ritz B; Sterling TR
    J Infect Dis; 2005 Sep; 192(6):950-7. PubMed ID: 16107946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
    Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
    J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures.
    Hernán MA; Brumback BA; Robins JM
    Stat Med; 2002 Jun; 21(12):1689-709. PubMed ID: 12111906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
    Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
    Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death.
    Westreich D; Cole SR; Young JG; Palella F; Tien PC; Kingsley L; Gange SJ; Hernán MA
    Stat Med; 2012 Aug; 31(18):2000-9. PubMed ID: 22495733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell response of advanced aids patients after highly active antiretroviral therapy.
    Wang AX; Li TS; Cao YZ; Han Y; Qiu ZF; Xie J
    Chin Med Sci J; 2005 Dec; 20(4):223-5. PubMed ID: 16422247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.
    MacArthur RD; Perez G; Walmsley S; Baxter JD; Mullin CM; Neaton JD; ;
    HIV Clin Trials; 2005; 6(3):127-35. PubMed ID: 16192247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural accelerated failure time models for survival analysis in studies with time-varying treatments.
    Hernán MA; Cole SR; Margolick J; Cohen M; Robins JM
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):477-91. PubMed ID: 15660442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.
    Bogaards JA; Weverling GJ; Geskus RB; Miedema F; Lange JM; Bossuyt PM; Goudsmit J
    Antivir Ther; 2003 Feb; 8(1):43-50. PubMed ID: 12713063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Highly Active Antiretroviral Therapy and Type of Infectious Respiratory Disease and All-Cause In-Hospital Mortality in Patients with HIV/AIDS: A Case Series.
    Báez-Saldaña R; Villafuerte-García A; Cruz-Hervert P; Delgado-Sánchez G; Ferreyra-Reyes L; Ferreira-Guerrero E; Mongua-Rodríguez N; Montero-Campos R; Melchor-Romero A; García-García L
    PLoS One; 2015; 10(9):e0138115. PubMed ID: 26379281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.